End-Users Should Have Greater Input In Sharps Safety Purchasing - Panel
This article was originally published in The Gray Sheet
Executive SummaryRapid advances in sharps safety technology are making it more imperative that frontline health care workers have more input in facility decisions to purchase the devices, panelists at the Premier Sharps Safety Forum agreed April 5 in Crystal City, Virginia.
You may also be interested in...
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.